Blockchain Registration Transaction Record

Dogwood Therapeutics Advances Non-Opioid Pain Treatments with Key Pipeline Progress

Dogwood Therapeutics reports Q1 2026 results, advancing Halneuron Phase 2b for chemotherapy-induced pain and SP16 Phase 1b. Non-opioid pain treatments show promise.

This news matters because it highlights progress in developing non-opioid alternatives for pain management, particularly for chemotherapy-induced neuropathy. With the opioid crisis ongoing, new treatments like Halneuron and SP16 offer hope for patients seeking effective pain relief without addiction risks. Dogwood's advancements could transform care for cancer survivors and chronic pain sufferers, potentially reducing reliance on opioids.